Dealmaking Quarterly Statistics, Q2 2020

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2020

During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.

Quarterly Stats_1200x675

Biopharma merger and acquisition value for the second quarter of 2020 reached $5.9bn, a 14% decline from Q1’s $6.9bn (see Exhibit 1). At the top (making up about a third of this total) was Novo Nordisk AS’s $2.1bn buy of private US biotech Corvidia Therapeutics [See Deal] Novo is paying $725m in cash up front and could provide earn-outs of up to $1.375bn upon the achievement of milestones tied to Corvidia's ziltivekimab, its Phase II candidate for chronic kidney disease. Also see "Novo Nordisk Fortifies Cardio-Renal Efforts With Corvidia Buy" - Scrip, 11 June, 2020.

Exhibit 1.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.